ImClone, Bristol-Myers to Delay Filing

Drugmakers ImClone Systems Inc. and Bristol-Myers Squibb Co. said Tuesday that they will delay applying to sell their Erbitux drug as a treatment for certain types of head and neck cancer while they further review study data. The companies said they now plan to file an application with the Food and Drug Administration by year-end, instead of in the second quarter as previously forecast. Erbitux is currently approved by the FDA to treat advanced colorectal cancer that has spread to other parts of the body.

Forbes (http://www.forbes.com/home_asia/feeds/ap/2005/04/12/ap1941667.html)